A major study demonstrates that respiratory syncytial virus (RSV) vaccination during pregnancy reduces infant hospitalization risk by more than 80%, providing significant protection against severe respiratory illness in newborns. RSV is a leading cause of infant hospitalization worldwide and can cause lower respiratory tract infections such as bronchiolitis and pneumonia in infants and young children. Early-life RSV infection is linked to potential long-term health consequences including recurrent wheeze or asthma, repeat hospital admissions, and impaired lung health. The findings suggest maternal vaccination offers a powerful preventive strategy against a virus that causes severe respiratory illness in vulnerable newborn populations.
RSV as a Major Health Threat to Infants
- ▪Respiratory syncytial virus (RSV) is a leading cause of infant hospitalization worldwide
- ▪Respiratory syncytial virus (RSV) can cause lower respiratory tract infections (LRTIs) such as bronchiolitis and pneumonia in infants and young children
- ▪Respiratory syncytial virus (RSV) can cause severe respiratory illness in infants and young children
Long-term Health Consequences of Early RSV Infection
- ▪Early-life respiratory syncytial virus (RSV) infection is linked to potential impaired lung health
- ▪Early-life respiratory syncytial virus (RSV) infection is linked to potential repeat hospital admissions
- ▪Early-life respiratory syncytial virus (RSV) infection is linked to potential recurrent wheeze or asthma
Perspective of Public health officials and maternal health advocates
- ▪Maternal respiratory syncytial virus (RSV) vaccination offers significant protection against severe respiratory illness in newborns
- ▪Maternal respiratory syncytial virus (RSV) vaccination during pregnancy reduces infant hospitalization risk by more than 80%
- ▪Maternal respiratory syncytial virus (RSV) vaccination represents a major advancement in preventing infant respiratory disease
Story comments
Loading comments…